After two years of funding drought, the biotech industry is stirring back to life—and contract research organisations (CROs) are reaping the rewards. Companies such as Danaher, Medpace, IQVIA, ICON and Thermo Fisher Scientificreported strong second‑quarter earnings, driven by steady demand for drug development services reuters.com. Analysts say the turnaround reflects a gradual improvement in biotech and pharmaceutical funding; venture capital flows ticked up from April through June, easing pressure on early‑stage companies reuters.com. The S&P Biotech ETF remains roughly 50 % below its 2021 peak, but the macro environment appears more stable, encouraging sponsors to restart trials reuters.com.
CROs have responded by raising revenue guidance and reporting lower project cancellations reuters.com. Demand is particularly robust for early‑phase services and complex clinical trials targeting oncology and rare diseases. Some caution that tight labour markets and geopolitical tensions could still pose challenges, but for now, the sector looks poised for expansion. With drugmakers outsourcing more research to keep costs down and accelerate timelines, CROs may continue to enjoy a renaissance even as broader markets wobble.
